Document Detail


Economic Evaluation of Levosimendan Versus Dobutamine for the Treatment of Acute Heart Failure in Italy.
MedLine Citation:
PMID:  23233357     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
INTRODUCTION: Inodilators are the first-choice class of drugs for the treatment of acute heart failure (AHF). Levosimendan is a relatively recent inodilatory agent, presenting superior outcomes in comparison with traditional inotropes. METHODS: An economic evaluation of levosimendan for the treatment of AHF in Italy was performed. In a retrospective study conducted on patients with AHF admitted to a teaching hospital in Rome, two groups were derived from an observational registry: 147 patients treated with levosimendan and 145 treated with dobutamine. Follow-up was at 1 year after treatment. In the reference study looked at in this paper, treatment with levosimendan reduced mean length of stay (LOS) by 1.5 days (P < 0.05). Reduction in the rehospitalization rate was 6.7% (P < 0.05). Mortality rate at 1 month was reduced by 4.8% (P < 0.05). RESULTS: Based on the reference study, a cost analysis from the hospital perspective was carried out. The incremental cost of treatment with levosimendan (<euro>697) was equivalent to the incremental savings (<euro>694), the latter being obtained from the reduction in LOS (<euro>508) and rehospitalization rate (<euro>186). CONCLUSION: Despite the limitations of this study, and even neglecting all nonmonetary health gains as additional outcomes, levosimendan appears to be a competitive alternative compared with dobutamine for the treatment of AHF in the Italian hospital setting.
Authors:
Carlo Lucioni; Alessandra D'Ambrosi; Silvio Mazzi; Piero Pollesello; Marjo Apajasalo; Francesco Fedele
Related Documents :
8516747 - The preservation of hearing and facial nerve function in a consecutive series of unilat...
24368097 - Treatment of corneal ulcers with platelet rich plasma.
24000077 - Comparison of automated red cell exchange transfusion and simple transfusion for the tr...
23766627 - Six-month results from a phase iii randomized trial of fixed-combination brinzolamide 1...
8516747 - The preservation of hearing and facial nerve function in a consecutive series of unilat...
22131777 - Comparison of the outcome of repeat trabeculectomy with adjunctive mitomycin c and init...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-6
Journal Detail:
Title:  Advances in therapy     Volume:  -     ISSN:  1865-8652     ISO Abbreviation:  Adv Ther     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Springer Healthcare, via Lanino 5, 20144, Milano, Italy, carlo.lucioni@springer.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increasing participation in cervical cancer screening: Telephone contact with long-term non-attendee...
Next Document:  The yield of EUS-FNA in undiagnosed upper abdominal adenopathy is very high.